Table A3.

Comparison of Key Variables Between High- and Low-Volume Light-Chain Amyloidosis Transplantation Centers

Variable	Center Experience, No. of Transplantations				P
	< 4 (n = 91)		≥ 4 (n = 66)
	No.	%	No.	%
Age at transplantation, years					.60
18-39	3	3	5	8
40-49	13	14	6	9
50-59	40	44	27	41
60-65	19	21	17	26
≥ 66	16	18	11	17
Karnofsky score					.68
80-100	71	78	52	79
< 80	13	14	7	11
Missing	7	8	7	11
Time from diagnosis to transplantation, months					.49
< 6	63	69	40	61
6-12	18	20	18	27
12-24	10	11	8	12
Cardiac involvement					.24
Yes	37	41	22	33
No	32	35	32	48
Missing	22	24	12	18
Renal involvement					.65
Yes	68	75	52	79
No	11	12	5	8
Missing	12	13	9	14
Organ involvement					.13
0	1	1	2	3
1	29	32	23	35
2	36	40	15	23
3	18	20	15	23
4	7	8	11	17
Hematopoietic cell transplantation–comorbidity index					.15
0	25	27	8	12
1	10	11	9	14
2	13	14	14	21
3	13	14	7	11
4	24	26	19	29
Missing	6	7	9	14
Melphalan dose, mg/m2					.20
< 140	35	38	34	52
140-180	18	20	13	20
> 180	37	41	17	26
Missing	1	1	2	3
Chemotherapy					.09
No chemotherapy	65	71	40	61
Melphalan based	6	7	9	14
Thalidomide based	2	2	7	11
Lenalidomide based	9	10	4	6
Bortezomib based	9	10	6	9

NOTE. Center experience was measured by the mean number of light-chain transplantations performed at centers between 2009 and 2012. High volume was four or more transplantations per year, and low volume was four or fewer transplantations per year.